(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...
Stats | |
---|---|
Dagens volum | 4.00 |
Gjennomsnittsvolum | 1 120.00 |
Markedsverdi | 11.48B |
EPS | $9.72 ( 2023-11-06 ) |
Last Dividend | $0.603 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 39.22 |
ATR14 | $0 (0.00%) |
Eisai Co., Ltd. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Eisai Co., Ltd. Økonomi
Annual | 2023 |
Omsetning: | $744.40B |
Bruttogevinst: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2023 |
Omsetning: | $744.40B |
Bruttogevinst: | $543.48B (73.01 %) |
EPS: | $193.31 |
FY | 2022 |
Omsetning: | $756.23B |
Bruttogevinst: | $569.79B (75.35 %) |
EPS: | $167.27 |
FY | 2021 |
Omsetning: | $645.94B |
Bruttogevinst: | $484.63B (75.03 %) |
EPS: | $146.95 |
Financial Reports:
No articles found.
Eisai Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.555 (N/A) |
$0 (N/A) |
$0.603 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.784 | 2014-03-27 |
Last Dividend | $0.603 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 2018-05-24 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $11.60 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.79 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.00 | |
Div. Directional Score | 7.04 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RNMBY | Ex Dividend Knight | 2023-05-10 | Annually | 0 | 0.00% | |
FFDF | Ex Dividend Knight | 2023-08-01 | Quarterly | 0 | 0.00% | |
WBHC | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
LYBC | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
CLLNY | Ex Dividend Junior | 2023-06-16 | Semi-Annually | 0 | 0.00% | |
SLVYY | Ex Dividend Knight | 2023-05-15 | Semi-Annually | 0 | 0.00% | |
HALMY | Ex Dividend Knight | 2023-07-14 | Semi-Annually | 0 | 0.00% | |
AMADY | Ex Dividend Knight | 2023-07-11 | Annually | 0 | 0.00% | |
NDBKY | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
CRZBY | Ex Dividend Junior | 2023-06-01 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0606 | 1.500 | 8.79 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0346 | 1.200 | 8.85 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0546 | 1.500 | -0.504 | -0.756 | [0.1 - 1] |
payoutRatioTTM | 1.011 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.38 | 0.800 | 3.10 | 2.48 | [1 - 3] |
quickRatioTTM | 1.697 | 0.800 | 4.72 | 3.78 | [0.8 - 2.5] |
cashRatioTTM | 1.025 | 1.500 | 5.42 | 8.12 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 25.36 | 1.000 | 1.719 | 1.719 | [3 - 30] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.203 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.789 | 1.000 | 0.176 | 0.176 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0790 | 1.000 | -0.419 | -0.419 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.372 | 1.000 | 9.04 | 9.04 | [0.2 - 2] |
assetTurnoverTTM | 0.572 | 0.800 | 9.52 | 7.62 | [0.5 - 2] |
Total Score | 10.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.99 | 1.000 | 6.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0546 | 2.50 | -0.324 | -0.756 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 166.26 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0168 | 1.500 | 9.58 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 215.91 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.011 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.0162 | 1.500 | -3.23 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0826 | 1.000 | -0.434 | 0 | [0.1 - 0.5] |
Total Score | 4.00 |
Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.